AMR Efforts in Q3 2024
RALEIGH, N.C. | October 24, 2024 – The Kineticos AMR Accelerator Fund I (“KAMRA”) envisions a World Without Antimicrobial ResistanceTM (“AMR”). Launched in 2023, KAMRA focuses on supporting innovators to address the serious global problem of AMR. Since then, there is a growing awareness of the AMR issue, as exemplified in recent scientific publications, and the 79th UN General Assembly in September, which called for sustainable national financing to address this urgent healthcare need.
Notably, papers were published in the Lancet, one of the world’s leading medical journals.
- Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 – The Lancet
- Antimicrobial resistance: a concise update – The Lancet Microbe
- Promoting sustainable national action to tackle antimicrobial resistance: a proposal to develop an antimicrobial resistance accountability index – The Lancet Microbe
- Antimicrobial resistance: now is the time to revisit global commitments – The Lancet
In a report published September 25, 2024 from the Center for Global Development, it is predicted that AMR health costs would rise to US$ 325 billion and the global economy would be US$ 1.7 trillion smaller in 2050: Forecasting the Fallout from AMR: Economic Impacts of Antimicrobial Resistance in Humans | Center For Global Development (cgdev.org)
These publications coincided with the UN General Assembly High-Level Meeting on antimicrobial resistance held on September 26, 2024: UN General Assembly High-Level Meeting on antimicrobial resistance 2024 and their political declaration on AMR.
An overview of the problem appeared in the New York Times on Sept. 30, 2024, The Global Threat of Antibiotic Resistance, that emphasized the lack of a market for new antibiotics, and how it is stifling the introduction of new antibiotics and diagnostic tests that would be beneficial in the fight against AMR.
The awareness has even come to Broadway theaters with the international musical Lifeline a Musical debuted from August 28-September 28th. It was inspired by the life of Sir Alexander Fleming and true stories about the impact of antibiotic resistance.
In the United States, the House Budget Committee held a bipartisan roundtable entitled, Threats to Modern Medicine: Examining the Budgetary Effects of Antimicrobial Resistance and the Broken Antibiotic Development Pipeline. The House Budget Committee is leading the charge to examine new approaches and corresponding budgetary effects on policies that aim to increase stewardship and inject needed incentives for antimicrobial drug development.
While all of this news continues to drive awareness and focus on AMR, there is still much more work needed to build a self-sustaining commercial market. The growing awareness and discussions of how AMR complicates the delivery of and increases the cost of healthcare globally are pieces to solving AMR. However, further investment is needed from large pharma, and the private and public markets in order to successfully deliver new antimicrobial therapeutic and analytic technologies to help patients. As one of the few early-stage AMR investors, the KAMRA fund partners, through investment and collaboration, with innovative companies developing disruptive technologies that will positively impact the issues that these papers, articles, and committees continue to discuss.
About Kineticos Life Sciences
Kineticos envisions A World Without AMRTM. We are entrepreneurs helping entrepreneurs build companies to improve patient outcomes. Kineticos invests in life science companies focused on significant, unmet medical needs across contract services, manufacturing, equipment, and therapeutic companies. Kineticos strives to disrupt how drugs are developed, diseases are diagnosed, and patients are treated.
Media Contact
investorrelations@kineticos.com